Personal information

Other IDs

Scopus Author ID: 56572558900
Loop profile: 2067888

Activities

Collapse all

Employment (4)

Bristol Myers Squibb: Seattle, Washington, US

Scientist (Immuno-oncology)
Employment
Source: Self-asserted source
Danielle Lussier

Inimmune: Missoul, Montana, US

2020 to present | Lead Investigator (Immuno-oncology)
Employment
Source: Self-asserted source
Danielle Lussier

Celgene: Seattle, WA, US

2017 to 2020 | Scientist (Immuno-oncology)
Employment
Source: Self-asserted source
Danielle Lussier

Washington University in Saint Louis: Saint Louis, MO, US

2015-06 to 2017 | Post-doc (Pathology and Immunology)
Employment
Source: Self-asserted source
Danielle Lussier

Education and qualifications (3)

Washington University in Saint Louis: Saint Louis, MO, US

2015-06 to present | Post-doc (Pathology and Immunology)
Education
Source: Self-asserted source
Danielle Lussier

Arizona State University: Tempe, AZ, US

2010-08 to 2015-05 | PhD (Molecular and Cellular Biology)
Education
Source: Self-asserted source
Danielle Lussier

University of Texas at Austin: Austin, TX, US

2005-08 to 2009-05 | Bachelors of Science (Neurobiology)
Education
Source: Self-asserted source
Danielle Lussier

Works (10)

Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads

PNAS
2021 | Journal article
Source: Self-asserted source
Danielle Lussier

Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads

Proceedings of the National Academy of Sciences
2021-06-15 | Journal article
DOI: 10.1073/pnas.2102611118
Contributors: Danielle M. Lussier; Elise Alspach; Jeffrey P. Ward; Alexander P. Miceli; Daniele Runci; J. Michael White; Cedric Mpoy; Cora D. Arthur; Heather N. Kohlmiller; Tyler Jacks et al.
Source: check_circle
Crossref

MHC-II neoantigens shape tumour immunity and response to immunotherapy.

Nature
2019-10-23 | Journal article
DOI: 10.1038/s41586-019-1671-8
PMID: 31645760
PMC: PMC6858572
Source: Self-asserted source
Danielle Lussier

Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.

Cold Spring Harbor perspectives in biology
2019-03-01 | Journal article
DOI: 10.1101/cshperspect.a028480
PMID: 29661791
PMC: PMC6396335
Source: Self-asserted source
Danielle Lussier

Cancer Immunosurvelliance: immunoediting.

Encyclopedia of Immunology
2016 | Book chapter
Source: Self-asserted source
Danielle Lussier

Progress and opportunities for immune therapeutics in osteosarcoma.

Immunotherapy
2016-10-01 | Journal article
DOI: 10.2217/imt-2016-0048
PMID: 27605071
Source: Self-asserted source
Danielle Lussier

Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.

BMC cancer
2016-05-13 | Journal article
DOI: 10.1186/s12885-016-2337-7
PMID: 27178315
PMC: PMC4866042
Source: Self-asserted source
Danielle Lussier

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.

2015 | Journal article
DOI: 10.1186/s40425-015-0067-z
PMID: 25992292
PMC: PMC4437699
Contributors: Lussier DM; Johnson JL; Hingorani P; Blattman JN
Source: Self-asserted source
Danielle Lussier via Europe PubMed Central

Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.

2015-04 | Journal article
DOI: 10.1097/CJI.0000000000000065
PMID: 25751499
Contributors: Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
Source: Self-asserted source
Danielle Lussier via Europe PubMed Central

Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions.

2013 | Journal article
PMC: PMC3991345
Contributors: Lussier DM; Nieves LM; McAfee MS; Hyunh TP; Holechek SA; Hingorani P; Blattman JN
Source: Self-asserted source
Danielle Lussier via Europe PubMed Central
How many people are using ORCID?